12 unknown. 12 Phase 1, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 12 | Unknown 12 |
| Phase 2 | 7 | Unknown 7 |
Follow Immunotherapy: new trials by email Literature Review of Immunotherapy trials Research Report on Immunotherapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Induction Toripalimab and Chemotherapy in Locally Advanced Cervical Cancer Toripalimab - Cervical Cancer, Induction Chemotherapy | Phase 1 / Phase 2 | Unknown | Tianjin Medical University Cancer Institute and Hospital | 20 | 2023-11-01 | 2025-03-11 |
| Disitamab Vedotin, Fruquintinib and Tislelizumab in Second-line Treatment for HER2-positive MGC Disitamab Vedotin combined with fruquintinib and Tislelizumab - HER2-positive Gastric Cancer, Immunotherapy | Phase 1 / Phase 2 | Unknown | Fudan University | 43 | 2023-05-09 | 2023-08-09 |
| Clinical Study of CAIX-targeted CAR-T Cells in the Treatment of Advanced Renal Cell Carcinoma CAR-T cell immunotherapy - Immunotherapy | Phase 1 | Unknown | The Affiliated Hospital of Xuzhou Medical University | 20 | 2021-10-01 | 2021-07-20 |
| Hypomemylating Agents Combination With eDC Therapy for Elderly Patients With Myelodysplastic Syndrome DC vaccine - Myelodysplastic Syndromes, Dendritic Cell | Phase 1 | Unknown | Affiliated Hospital to Academy of Military Medical Sciences | 40 | 2021-07-01 | 2021-08-11 |
| Preoperative Short Course Radiotherapy With Chemotherapy and Camerelizumab in Locally Advanced Rectal Cancer Camrelizumab - Rectal Cancer, Radiotherapy | Phase 1 / Phase 2 | Unknown | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 30 | 2019-11-10 | 2020-11-30 |
| PD-1 Inhibitors Consolidation in Extensive-stage Small Cell Lung Cancer PD-1 inhibitor JS-001 - Extensive-stage Small Cell Lung Cancer, Radiotherapy | Phase 1 | Unknown | Chinese Academy of Medical Sciences | 6 | 2019-06-01 | 2019-06-04 |
| Regorafenib Plus PD-1 Inhibitor in Patients With Colorectal Cancer Regorafenib and PD-1 inhibitor - Colorectal Cancer, Immunotherapy | Phase 1 / Phase 2 | Unknown | Shanghai Changzheng Hospital | 120 | 2019-03-01 | 2020-12-30 |
| Exploring Cancer-Associated Thromboembolism Prognosis Biomarkers and Polymorphisms Palbociclib, Rivaroxaban, SNP - Cancer, Solid Tumor | Phase 1 | Unknown | Lebanese University | 500 | 2019-02-01 | 2023-10-06 |
| Combination of Proton Therapy With Immunotherapy in Multiple Metastases Cancer Radiation: Proton Therapy+PD-1 Ab - Proton Therapy, Immunotherapy | Phase 1 / Phase 2 | Unknown | Peking University First Hospital | 30 | 2019-01-01 | 2018-12-05 |
| Combination of Hypofractionated Proton Therapy With Immunotherapy Radiation+PD-1 Ab - Proton Therapy, Immunotherapy | Phase 1 / Phase 2 | Unknown | Peking University First Hospital | 30 | 2019-01-01 | 2018-12-05 |
| NK Cells Infusion for Advanced Malignancies NK cells infusion - Immunotherapy | Phase 1 | Unknown | Anhui Provincial Hospital | 50 | 2018-07-01 | 2018-08-08 |
| Study of Sting Challenge and Serological Responses to Jack Jumper Venom Immunotherapy With Inulin as Adjuvant (Jumpvax) Delta-inulin, Dose finding comparison - Ant Sting, Immunotherapy | Phase 1 / Phase 2 | Unknown | Central Adelaide Local Health Network Incorporated | 40 | 2016-10-01 | 2020-08-11 |
Breast Neoplasms (1) · Carcinoma, Hepatocellular (1) · Cardiovascular Diseases (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Immune System Diseases (1) · Inflammation (1) · Lung Neoplasms (1) · Myelodysplastic Syndromes (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Prostatic Neoplasms (1) · Rectal Neoplasms (1) · Small Cell Lung Carcinoma (1) · Thromboembolism (1)
Neoplasms (5) · Neoplasms by Site (5) · Digestive System Diseases (3) · Digestive System Neoplasms (3) · Gastrointestinal Diseases (3) · Gastrointestinal Neoplasms (3) · Intestinal Diseases (3) · Intestinal Neoplasms (3) · Colonic Diseases (2) · Colorectal Neoplasms (2) · Genital Diseases (2) · Lung Diseases (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Rectal Diseases (2)
Radiotherapy (2) · Drug Therapy (1) · HMPL-013 (1) · Immune Checkpoint Inhibitors (1) · Immunotherapy, Adoptive (1) · Rivaroxaban (1) · camrelizumab (1) · delta inulin (1) · lentiviral minigene vaccine of COVID-19 coronavirus (1) · palbociclib (1) · regorafenib (1) · tislelizumab (1) · toripalimab (1)
Peking University First Hospital (2) · Affiliated Hospital to Academy of Military Medical Sciences (1) · Anhui Provincial Hospital (1) · Central Adelaide Local Health Network Incorporated (1) · Chinese Academy of Medical Sciences (1) · Fudan University (1) · Lebanese University (1) · Shanghai Changzheng Hospital (1) · The Affiliated Hospital of Xuzhou Medical University (1) · Tianjin Medical University Cancer Institute and Hospital (1) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1)
China (8) · Australia (1) · Lebanon (1)
Xianshu Gao, MD,PhD (2) · Hailong Li, M.D/Ph.D (1) · Jie Chen (1) · Junnian Zheng, M.D/Ph.D (1) · Liangding Hu, Prof. (1) · Nan Bi, MD (1) · Nehman Makdissy, Professor (1) · Pravin Hissaria, FRACP FRCPA (1) · Qing Zhang, Ph.D (1) · Tao Zhang, MD (1) · Yueyin Pan, PhD (1)
PMID 20889925, PMID 23256743, PMID 23423337, PMID 23515080, PMID 24790793, PMID 25317870, PMID 25939063, PMID 28031562, PMID 28541315, PMID 28843072, PMID 29048935, PMID 31110702, PMID 34725214, PMID 40346524, PMID 41748259